
    
      The primary objective of this study is to evaluate the efficacy and safety of OPN-375 186 Î¼g
      twice a day in adults with Bilateral Nasal Polyps using Nasoendoscopic video. The secondary
      objectives of this study are to evaluate the safety of OPN-375 via adverse event reports,
      vital signs, and nasal examination. In addition, to measure any change in subject symptoms
      and functioning from Baseline to 12 and 24 weeks during the study, using the Sinonasal
      Outcome Test -22 (SNOT-22), Patient's Global Impression of Change (PGIC), and measurement of
      nasal polyps by independent, blinded reader, and any changes throughout the study.
    
  